Abstract
Background. At the St Gallen meeting of 2001 it was agreed to select high-risk patients for adjuvant systemic therapy by lymph node status, tumor size, age, hormone receptor status, and histological grade. In The Netherlands it was chosen to use either the histological grade or the mitotic activity index (MAI). The aim of this study was to retrospectively evaluate the independent prognostic value of the MAI in primary breast cancer patients, who were not treated with adjuvant systemic therapy, on relapse-free survival (RFS) and overall survival (OS).
Patients and methods. The data of 137 systemically untreated patients with primary breast cancer diagnosed between 1992 and 1996, of whom MAI was assessed, were retrospectively collected. The MAI was correlated to classical prognostic factors and we determined the prognostic value of the MAI, the histological grade and other prognostic factors.
Results. The median observation time was 4.2 years. The MAI showed a positive correlation to lymph node status (P <; 0.001) and a negative correlation to age (P = 0.005), menopausal status (P <; 0.001) and the ER and PgR status (r s = −0.390 [ER], r s = −0.440 [PgR], both P < 0.001). A high MAI (≥ 15) predicted a reduced RFS and OS in the Kaplan–Meier analysis (P = 0.0070 and P = 0.0017, respectively). Also in the multivariate analysis, the MAI showed to be an independent predictor of poor RFS (P = 0.035), in addition to lymph node status. However, the MAI did not predict for OS, in contrast to tumor size and lymph node status.
Conclusion. The present study confirms that the MAI is an independent prognostic factor for RFS, but not for OS and may be useful for daily clinical practice.
Similar content being viewed by others
References
Fisher B, Bauer M, Wickerham DL, Redmond CK, Fisher ER: Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer: an NSABP update. Cancer 52: 1551-1557, 1983
Cady B, Stone MD, Schuler JG, Thakur R, Wanner MA, Lavin PT: The new era in breast cancer. Invasion, size, and nodal involvement dramatically decreasing as a result of mammographic screening. Arch Surg 131: 301-308, 1996
Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351: 1451-1467, 1996
Early Breast Cancer Trialists' Collaborative Group: Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 352: 930-942, 1998
Saez RA, McGuire WL, Clark CML: Prognostic factors in breast cancer. Semin Surg Oncol 5: 102-110, 1989
McGuire WL, Clark GM: Prognostic factors and treatment decisions in axillary-node-negative breast cancer. N Engl J Med 326: 1756-1761, 1992
Goldhirsch A, Glick JH, Gelber RD, Coates AS, Senn HJ: Meeting highlights: international consensus panel on the treatment of primary breast cancer. J Clin Oncol 19: 3817-3827, 2001
Bloom HJG, Richardson WW: Histological grading and prognosis in breast cancer. A study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 11: 359-377, 1957
Elston CW, Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19: 403-410, 1991
Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM, Ruby SG, O'Malley F, Simpson JF, Connolly JL, Hayes DF, Edge SB, Lichter A, Schnitt SJ: Prognostic factors in breast cancer. College of American pathologists consensus statement 1999. Arch Pathol Lab Med 124: 966-978, 2000
Younes M, Laucirica R: Lack of prognostic significance of histological grade in node-negative invasive breast carcinoma. Clin Cancer Res 3: 601-604, 1997
Bontenbal M, Nortier JWR, Beex LVAM, Bakker P, Hupperets PSGJ, Nooij MA, van Veelen H, Vreugdenhil G, Richel DJ, Blijham GH: Adjuvante systemische therapie voor patiënten met resectabel mammacarcinoom; richtlijn van het Nationaal Borstkanker Overleg Nederland en de Nederlandse Vereniging voor Medische Oncologie. Ned Tijdschr Geneeskd 144: 984-989, 2000
Baak JPA, van Dop H, Kurver PHJ, Hermans J: The value of morphometry to classic prognosticators in breast cancer. Cancer 56: 374-382, 1985
Uyterlinde AM, Schipper NW, Baak JPA, Peterse H, Matze E: Limited prognostic value of cellular DNA content to classical and morphometrical parameters in invasive ductal breast cancer. Am J Clin Pathol 89: 301-307, 1988
van der Linden JC, Lindeman J, Baak JPA, Meijer CJLM, Herman CJ: The multivariate prognostic index and nuclear DNA content are independent prognostic factors in primary breast cancer patients. Cytometry 10: 56-61, 1989
de Jong JS, van Diest PJ, Baak JPA: Number of apoptotic cells as a prognostic marker in invasive breast cancer. Br J Cancer 82: 368-373, 2000
de Jong JS, van Diest PJ, Baak JPA: Hot spot microvessel density and the mitotic activity index are strong additional prognostic indicators in invasive breast cancer. Histopathology 36: 306-312, 2000
Lipponen PK, Collan Y, Eskelinen MJ: Volume corrected mitotic index (M/V index), mitotic activity index (MAI), and histological grading in breast cancer. Int Surg 76: 245-249, 1991
Aaltomaa S, Lipponen P, Eskelinen M, Kosma VM, Marin S, Alhava E, Syrjänen K: Prognostic factors after 5 years followup in female breast cancer. Oncology 49: 93-98, 1992
Eskelinen M, Lipponen P, Papinaho S, Aaltomaa S, Kosma VM, Klemi P, Syrjänen K: DNA flow cytometry, nuclear morphometry, mitotic indices and steroid receptors as independent prognostic factors in female breast cancer. Int J Cancer 51: 555-561, 1992
Baak JPA, Kurver PHJ, de Snoo-Nieuwlaat AJE, de Graef S, Makkink B, Boon ME: Prognostic indicators in breast cancer-morphometric methods. Histopathology 6: 327-339, 1982
Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958
Cox DR: Regression models and life-tables (with discussion). J R Statist Soc Ser B 34: 187-220, 1972
Baak JPA, van Diest PJ, Benraadt T, Matze-Cok E, Brugghe J, Schuurmans LT, Littooy JJ, other MMMCP collaborators: The multi-center morphometric mammary carcinoma project (MMMCP) in The Netherlands: value of morphometrically assessed proliferation and differentiation. J Cell Biochem Suppl 17G: 220-225, 1993
Haapasalo H, Pesonen E, Collan Y: Volume corrected mitotic index (M/V-index). The standard of mitotic activity in neoplasms. Path Res Pract 185: 551-554, 1989
Collan YUI, Kuopio T, Baak JPA, Becker R, Bogomoletz WV, Deverell M, van Diest P, van Galen C, Gilchrist K, Javed A, Kosma VM, Kujari H, Luzi P, Mariuzzi GM, Matze E, Montironi R, Scarpelli M, Sierra D, Sisti S, Toikkanen S, Tosi P, Whimster WF, Wisse E: Standardized mitotic counts in breast cancer. Evaluation of the method. Path Res Pract 192: 931-941, 1996
van Diest PJ, Baak JPA, Matze-Cok P, Wisse-Brekelmans ACM, van Galen CM, Kurver PHJ, Bellot SM, Fijnheer J, van Gorp LHM, Kwee WS, Los J, Peterse JL, Ruitenberg HM, Schapers RFM, Schipper MEI, Somson JG, Willig AWPM, Ariens TH: Reproducibility of mitosis counting in 2469 breast cancer specimens: results from the multicenter morphometric mammary carcinoma project. Hum Pathol 23: 603-607, 1992
Brown RW, Allred DC, Clark GM, Osborne CK, Hilsenbeck SG: Prognostic value of Ki-67 compared to S-phase fraction in axillary node-negative breast cancer. Clin Cancer Res 2: 585-592, 1996
Clahsen PC, van de Velde CJH, Duval C, Pallud C, Mandard AM, Delobelle-Deroide A, van den Broek L, van de Vijver MJ: The utility of mitotic index, oestrogen receptor and Ki-67 measurements in the creation of novel prognostic indices for node-negative breast cancer. Eur J Surg Oncol 25: 356-363, 1999
Pinto AE, Andréeureka S, Pereira T, Nóbrega S, Soares J: Prognostic comparative study of S-phase fraction and Ki-67 index in breast carcinoma. J Clin Pathol 54: 543-549, 2001
Sundquist M, Thorstenson S, Brudin L, Ståral O, Nordenskjöld B: A comparison between flow cytometris assessment of Sphase fraction and Nottingham histologic grade as prognostic instruments in breast cancer. Breast Cancer Res Treat 63: 11-15, 2000
Silvestrini R, Diadone MG, Luisi A, Boracchi P, Mezzetti M, Di Fronzo G, Andreola S, Salvadori B, Veronesi U: Biological and clinicopathological factors as indicators of specific relapse types in node-negative breast cancer. J Clin Oncol 13: 697-704, 1995
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Manders, P., Bult, P., Sweep, C. et al. The Prognostic Value of the Mitotic Activity Index in Patients with Primary Breast Cancer Who were not Treated with Adjuvant Systemic Therapy. Breast Cancer Res Treat 77, 77–84 (2003). https://doi.org/10.1023/A:1021138801890
Issue Date:
DOI: https://doi.org/10.1023/A:1021138801890